ReviewPharmacology & therapeutics2021
Updates on community acquired pneumonia management in the ICU.
Review in Pharmacology & therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05356494 (Comparisons Effects of Postural Drainage and Positive Expiratory Pressure Technique in Community Acquired Pneumonia.), which is not on this map. Cited by 100 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparisons Effects of Postural Drainage and Positive Expiratory Pressure Technique in Community Acquired Pneumonia.
Who cites it
100 citing papers in PubMed, 7 syntheses or guidelines pooled it, 190 citations in OpenAlex.
- Efficacy of traditional Chinese medicine in treating severe pneumonia: A meta-analysis and systematic review.Medicine · 2026Pooled it
- Risk factors for drug-resistant pathogens in community-acquired pneumonia: systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Efficacy and safety of modified Xuanbai Chengqi Decoction as an adjunctive treatment for severe pneumonia: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Risk prediction models for mortality in patients with severe pneumonia: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Association between various types of corticosteroids and mortality for severe community-acquired pneumonia in adults: a systematic review and network meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Chinese herbal compound for multidrug-resistant or extensively drug-resistant bacterial pneumonia: a meta-analysis and trial sequential analysis with association rule mining to identify core herb combinations.Frontiers in pharmacology · 2023Pooled it
- Clinical values of metagenomic next-generation sequencing in patients with severe pneumonia: a systematic review and meta-analysis.Frontiers in cellular and infection microbiology · 2023Pooled it
- Traditional Chinese Medicine treatment with syndrome differentiation for patients with severe community-acquired pneumonia: a multicenter, randomized, placebo-controlled trial.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Trial
- Fibrinolysis Resistance After Injury Is a Risk Factor for a Hospital-Acquired Pneumonia-Like Disease Pattern.Surgical infections · 2024Trial
- MiR-342-3p Attenuates Inflammation and Pyroptosis in Severe Community-Acquired Pneumonia by Targeting EP300.Biochemical genetics · 2026Article
- Venous Thromboembolism in Severe Community-Acquired Pneumonia at High-Altitude Areas: Prevalence, Risk and Outcome.The clinical respiratory journal · 2026Article
- Correlation between NRS-2002 scores and PD-1/CTLA-4 expression levels in patients with community-acquired pneumonia.Scientific reports · 2026Article
- Predictive value of critical illness scores for outcomes of patients with community-acquired pneumonia: analysis of critical care data from the MIMIC-IV database.BMC pulmonary medicine · 2026Article
- Clinical characteristics and risk factors associated with mortality in patients with severe community-acquired pneumonia in the intensive care unit.Journal of thoracic disease · 2026Article
- Therapeutic effect of eravacycline against carbapenem-resistant hypervirulentAntimicrobial agents and chemotherapy · 2026Article
- Prognostic factors for severe community-acquired pneumonia in high altitude areas.Scientific reports · 2026Article
- The impact of the timing of mNGS-guided antibiotic adjustment on clinical outcomes in ICU patients with severe community-acquired pneumonia: a retrospective study.Annals of clinical microbiology and antimicrobials · 2026Article
- Red Blood Cell Fragmentation Mimicking Platelet Recovery in a Patient With Severe Pneumonia.Clinical case reports · 2026Article
- Prognostic value of IL-6, HMGB1, and TLR4 in bronchoalveolar lavage fluid of patients with community-acquired pneumonia.American journal of translational research · 2026Article
- Predictors of ICU Length of Stay in Patients with Severe Pneumonia: A Six-Year Retrospective Cohort Study Focusing on Traditional Chinese Medicine Adjuvant Therapy.International journal of general medicine · 2026Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While the world is grappling with the consequences of a global pandemic related to SARS-CoV-2 causing severe pneumonia, available evidence points to bacterial infection with Streptococcus pneumoniae as the most common cause of severe community acquired pneumonia (SCAP). Rapid diagnostics and molecular testing have improved the identification of co-existent pathogens. However, mortality in patients admitted to ICU remains staggeringly high. The American Thoracic Society and Infectious Diseases Society of America have updated CAP guidelines to help streamline disease management. The common theme is use of timely, appropriate and adequate antibiotic coverage to decrease mortality and avoid drug resistance. Novel antibiotics have been studied for CAP and extend the choice of therapy, particularly for those who are intolerant of, or not responding to standard treatment, including those who harbor drug resistant pathogens. In this review, we focus on the risk factors, microbiology, site of care decisions and treatment of patients with SCAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.